Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice

Liver International

Volumn 35, Issue 3, 2015, Pages 805-815

  Yoon, Seung Kew ^a   Seo, Yong Bok ^b   Im, Se Jin ^b   Bae, Si Hyun ^a   Song, Myeong Jun ^a   You, Chan Ran ^a   Jang, Jung Won ^a   Yang, Se Hwan ^c   Suh, You Suk ^c   Song, Ji Soo ^d   Kim, Byong Moon ^d   Kim, Chae Young ^d   Jeong, Sook Hyang ^e   Sung, Young Chul ^b,c  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b Pohang University of Science and Technology (POSTECH)   (South Korea)

^c POSTECH Biotech Center   (South Korea)

^d Dong A Pharmaceutical Company   (South Korea)

^e Seoul National University Bundang Hospital   (South Korea)

Author keywords

Chronic infection; DNA vaccine; Hepatitis B; Phase I; T cell response

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CYTOKINE; DNA VACCINE; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LACTATE DEHYDROGENASE; VIRUS DNA; ADENINE; PHOSPHONIC ACID DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BAGG ALBINO MOUSE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CODON; CYTOKINE RELEASE; DNA IMMUNIZATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLU LIKE SYNDROME; FLUORESCENCE ACTIVATED CELL SORTING; GENE DELETION; HEADACHE; HEPATITIS B; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; KOREAN (PEOPLE); LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER FUNCTION TEST; LYMPHADENOPATHY; MALE; MICTURITION DISORDER; MOUSE; NONHUMAN; ONCOGENE; ONYCHOLYSIS; OPEN STUDY; PATIENT COMPLIANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; SEROCONVERSION; SPLEEN CELL; T LYMPHOCYTE; TRANSGENIC MOUSE; TREATMENT OUTCOME; VACCINATION; VIRUS LOAD; ANALOGS AND DERIVATIVES; ANIMAL; ANTIBODY PRODUCTION; BLOOD; CONTROLLED STUDY; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADENINE; ADULT; ANIMALS; ANTIBODY FORMATION; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MIDDLE AGED; ORGANOPHOSPHONATES; T-LYMPHOCYTES; VACCINES, DNA; YOUNG ADULT;

EID: 84922699091     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12530     Document Type: Article

References (44)

1. Liang TJ. Hepatitis b the virus and disease. Hepatology 2009; 49(5 Suppl): S13-21.
2. Lok AS, Mcmahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
3. Kasper DL, Harrison TR. Harrison's Principles of Internal Medicine, 16th edn. New York: Mcgraw-Hill, Medical Pub. Division, 2005.
4. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(T)ide analogues. Gastroenterology 2009; 137: 1593-608 E1-2.
5. Mancini-Bourgine M, Fontaine H, Scott-Algara D, et al. Induction or expansion of T-cell responses by A hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 2004; 40: 874-82.
6. Vandepapeliere P, Lau GK, Leroux-Roels G, et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/As02 candidate vaccine and lamivudine. Vaccine 2007; 25: 8585-97.
7. Yang SH, Lee CG, Park SH, et al. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther 2006; 13: 1110-7.
8. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60.
9. Chisari FV. Rous-Whipple award lecture. viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol 2000; 156: 1117-32.
10. Webster GJ, Reignat S, Brown D, et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004; 78: 5707-19.
11. Kang ES, Kim CY, Kim SB, et al. In vivo kinetics and biodistribution of HB-110, a novel HBV DNA vaccine, after administration in mice. Arch Pharmacal Res 2007; 30: 355-60.
12. Araki K, Miyazaki J, Hino O, et al. Expression and replication of hepatitis B virus genome in transgenic mice. Proc Natl Acad Sci USA 1989; 86: 207-11.
13. Naito H, Hayashi S, Abe K. Rapid and specific genotyping system for hepatitis B virus corresponding to six major genotypes by PCR using type-specific primers. J Clin Microbiol 2001; 39: 362-4.
14. Penna A, Laccabue D, Libri I, et al. Peginterferon-alpha does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. J Hepatol 2012; 56: 1239-46.
15. Roederer M, Nozzi JL, Nason MC. Spice: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 2011; 79: 167-74.
16. Nagata T, Uchijima M, Yoshida A, Kawashima M, Koide Y. Codon optimization effect on translational efficiency of DNA vaccine in mammalian cells: analysis of plasmid DNA encoding a CTL epitope derived from microorganisms. Biochem Biophys Res Commun 1999; 261: 445-51.
17. Guidotti LG, Ando K, Hobbs MV, et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA 1994; 91: 3764-8.
18. Gruener NH, Lechner F, Jung MC, et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 2001; 75: 5550-8.
19. Michel ML, Deng Q, Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol 2011; 54: 1286-96.
20. Wherry EJ, Blattman JN, Murali-Krishna K, Van Der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003; 77: 4911-27.
21. Gust ID. Epidemiology of hepatitis B infection in the western Pacific and South East Asia. Gut 1996; 38(Suppl. 2): S18-23.
22. Liaw YF, Brunetto MR, Hadziyannis S. The natural history of chronic HBV infection and geographical differences. Antivir Ther 2010; 15(Suppl. 3): 25-33.
23. Wherry EJ, Ha SJ, Kaech SM, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007; 27: 670-84.
24. Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. Cell 2009; 138: 30-50.
25. Tang JR, Hsu HY, Lin HH, Ni YH, Chang MH. Hepatitis B surface antigenemia at birth: a long-term follow-up study. J Pediatr 1998; 133: 374-7.
26. Gasparoni A, Ciardelli L, Avanzini A, et al. Age-related changes in intracellular Th1/Th2 cytokine production, immunoproliferative T lymphocyte response and natural killer cell activity in newborns, children and adults. Biol Neonate 2003; 84: 297-303.
27. Ha SJ, Mueller SN, Wherry EJ, et al. Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med 2008; 205: 543-55.
28. Brooks DG, Lee AM, Elsaesser H, Mcgavern DB, Oldstone MB. IL-10 Blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J Exp Med 2008; 205: 533-41.
29. Low L, Mander A, Mccann K, et al. DNA Vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 2009; 20: 1269-78.
30. Vasan S, Hurley A, Schlesinger SJ, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 2011; 6: E19252.
31. Luckay A, Sidhu MK, Kjeken R, et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 2007; 81: 5257-69.
32. Rosati M, Valentin A, Jalah R, et al. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 2008; 26: 5223-9.
33. Peters MG, Hann H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101.
34. Deblaker-Hohe DF, Yamauchi A, Yu CR, Horvath-Arcidiacono JA, Bloom ET. IL-12 synergizes with IL-2 to induce lymphokine-activated cytotoxicity and perforin and granzyme gene expression in fresh human NK cells. Cell Immunol 1995; 165: 33-43.
35. Naume B, Gately M, Espevik T. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells. J Immunol 1992; 148: 2429-36.
36. Doherty DG, Norris S, Madrigal-Estebas L, et al. The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol 1999; 163: 2314-21.
37. Dunn C, Brunetto M, Reynolds G, et al. Cytokines induced during chronic hepatitis B virus infection promote A pathway for NK cell-mediated liver damage. J Exp Med 2007; 204: 667-80.
38. Guidotti LG, Mcclary H, Loudis JM, Chisari FV. Nitric oxide inhibits hepatitis B virus replication in the livers of transgenic mice. J Exp Med 2000; 191: 1247-52.
39. Takeda K, Hayakawa Y, Van Kaer L, et al. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci USA 2000; 97: 5498-503.
40. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000; 192: 921-30.
41. Ito H, Ando K, Nakayama T, et al. Role of valpha 14 NKT cells in the development of impaired liver regeneration in vivo. Hepatology 2003; 38: 1116-24.
42. Cavanaugh VJ, Guidotti LG, Chisari FV. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol 1997; 71: 3236-43.
43. Stoop JN, Van Der Molen RG, Baan CC, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005; 41: 771-8.
44. Xu D, Fu J, Jin L, et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006; 177: 739-47.